Compare Ecopetrol SA (EC) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecopetrol SA vs Novo Nordisk A/S — how do they compare? Ecopetrol SA trades at $17.01 (market cap $34.97B), while Novo Nordisk A/S trades at $46.34 (market cap $207.31B). The key difference: Novo Nordisk A/S is far larger — about 5.9× Ecopetrol SA's market cap, and Ecopetrol SA pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| EC | NVO | |
|---|---|---|
Market Cap | $34.97B | $207.31B |
Sector | Energy | Health |
52-Week High | $17.40 | $63.98 |
52-Week Low | $8.56 | $35.29 |
Enterprise Value | $65.28B | $222.02B |
Dividend Yield | 3.81% | 3.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ecopetrol (EC) trades at $16.78, down 3.56% on the day, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators are neutral. Fundamentally, revenue and net income have declined from 2022 peaks, though Q2 2026 earnings beat expectations. Recent news includes a cybersecurity incident and expansion efforts in Brazil, adding to volatility. Valuation ratios like P/E of 11.11 and P/S of 0.97 suggest potential undervaluation relative to historical metrics.
The outlook for EC is cautious; analyst consensus is mixed with a $15 price target below the current price. Risks include declining revenue trends, high debt levels, and operational disruptions from recent cyber threats. Opportunities lie in cost management and strategic acquisitions, but investor sentiment remains divided. The stock's near-term performance hinges on execution stability and energy market conditions.
Novo Nordisk (NVO) trades at $47.26, up 2.79% today, with a neutral technical signal and strong fundamentals including a P/E of 11.67 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but shares faced pressure from competitive concerns and pipeline setbacks. Cash flow remains robust with $10.81B net cash flow in 2025, while debt-to-asset ratio rose to 20.61% in 2024.
Outlook is mixed: solid profitability and analyst buy consensus (57.9%) support upside, but competition from Eli Lilly and pricing headwinds pose risks. Revenue growth is steady, with 2026 guidance lifted, yet investor sentiment is cautious amid operational challenges and high expectations for Wegovy pill performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ecopetrol SA
Ecopetrol SA is a vertically integrated oil company with operations in Latin America and the United States Gulf Coast. Based out of Colombia, the company explores, develops, and conducts production activities in various countries. Ecopetrol works as the primary operator or partner in a joint venture, in a host of assets held onshore and offshore. Along with production, the company refines and markets crude oils and byproducts produced from its fields. Crude products are moved by Ecopetrol through a series of pipelines throughout Colombia, along with a network of third-party production centers and facilities.
Read more on EC →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
